Insider Transactions in Q1 2024 at Ardelyx, Inc. (ARDX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2024
|
Mike Kelliher |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+50.0%
|
-
|
|
Mar 20
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
86,000
-21.55%
|
$602,000
$7.73 P/Share
|
|
Mar 15
2024
|
Robert Blanks Officer |
SELL
Bona fide gift
|
Direct |
1,000
-0.27%
|
-
|
|
Feb 26
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
5,183
-2.86%
|
$46,647
$9.2 P/Share
|
|
Feb 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
2,294
-1.25%
|
$18,352
$8.75 P/Share
|
|
Feb 20
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,017
-1.31%
|
$40,136
$8.75 P/Share
|
|
Feb 20
2024
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,341
-1.72%
|
$42,728
$8.75 P/Share
|
|
Feb 20
2024
|
Laura A Williams Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,803
-1.25%
|
$38,424
$8.75 P/Share
|
|
Feb 20
2024
|
Robert Ora Felsch Officer |
SELL
Open market or private sale
|
Direct |
2,352
-1.26%
|
$18,816
$8.75 P/Share
|
|
Feb 20
2024
|
Susan Rodriguez Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,928
-1.51%
|
$55,424
$8.75 P/Share
|
|
Feb 20
2024
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
4,432
-1.1%
|
$35,456
$8.75 P/Share
|
|
Feb 20
2024
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
5,017
-1.34%
|
$40,136
$8.75 P/Share
|
|
Feb 20
2024
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
22,917
-1.71%
|
$183,336
$8.75 P/Share
|
|
Feb 08
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
15,344
-3.84%
|
$138,096
$9.18 P/Share
|
|
Jan 16
2024
|
Laura A Williams Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,750
+23.58%
|
-
|
|
Jan 16
2024
|
Michael Raab President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
475,000
+26.13%
|
-
|
|
Jan 16
2024
|
Justin A Renz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
127,750
+29.17%
|
-
|
|
Jan 16
2024
|
Susan Rodriguez Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,750
+19.7%
|
-
|
|
Jan 16
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
70,120
+27.66%
|
-
|
|
Jan 16
2024
|
David P. Rosenbaum Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,750
+22.02%
|
-
|
|
Jan 16
2024
|
Robert Blanks Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,750
+23.2%
|
-
|
|
Jan 16
2024
|
Robert Ora Felsch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,120
+27.25%
|
-
|
|
Jan 16
2024
|
Elizabeth A Grammer Officer |
BUY
Grant, award, or other acquisition
|
Direct |
127,750
+24.05%
|
-
|
|
Jan 08
2024
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
30,000
-9.48%
|
$180,000
$6.64 P/Share
|